Table 3.
A glimpse of the clinical trials with dual blockade of the VEGF/VEGFR axis and the ERBB receptors in ovarian/genitourinary cancers
| Targets | Intervention | Clinical setting | Trial ID | Phase | Enrollment |
|---|---|---|---|---|---|
| VEGF & EGFR |
bevacizumab + erlotinib | advanced, refractory ovarian cancer | NCT00130520 | II | 40 |
| bevacizumab + erlotinib | recurrent or metastatic ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer | NCT00126542 | II | 35 | |
| experimental: carboplatin + paclitaxel + bevacizumab then bevacizumab experimental: carboplatin + paclitaxel + bevacizumab then bevacizumab + erlotinib |
first-line treatment of newly diagnosed advanced ovarian, fallopian tube, primary peritoneal cancer and papillary serous or clear cell Mullerian tumors | NCT00520013 | II | 60 | |
| VEGFR & ERBB2 |
experimental: combination arm (pazopanib plus lapatinib) active comparator: lapatinib monotherapy (lapatinib) active comparator: pazopanib monotherapy (pazopanib) |
recurrent or persistent advanced metastatic cervical cancer | NCT00430781 | II | 228 |